OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE

被引：0

作者：

Ong, Shin Yeu ^{[1
]}

Krisnadi, Cindy ^{[1
]}

Wang, Samuel Sherng Young ^{[1
]}

Chen, Yun Xin ^{[1
]}

Seng, Michaela Su-fern ^{[2
]}

Soh, Shui Yen ^{[2
]}

Chan, Esther Hian Li ^{[3
]}

Hwang, William Ying Khee ^{[1
]}

Ho, Aloysius Yew Leng ^{[1
]}

Lim, Francesca Lorraine Wei Inng ^{[1
]}

机构：

[1] Singapore Gen Hosp, Singapore, Singapore

[2] KK Womens & Childrens Hosp, Singapore, Singapore

[3] Natl Univ Canc Inst, Singapore, Singapore

来源：

BONE MARROW TRANSPLANTATION | 2024年 / 59卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

P120

引用

页码：226 / 226

页数：1

共 50 条

[41] Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients
Tu, Sanfang
Zhou, Lijuan
Huang, Rui
Zhou, Xuan
Yang, Jilong
He, Yanjie
Hu, Yuxing
Zhang, Honghao
Xie, Xiaoling
Li, Yuhua
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1437 - 1440
[42] CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia
Yao, Yao
Zhou, Jin
Li, Yanting
Shi, Sensen
Yu, Lei
Wu, Depei
Wang, Ying
ANNALS OF HEMATOLOGY, 2024, : 6031 - 6033
[43] Higher relative extranodal lymphoma burden is associated with shorter progression-free survival after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-Cell lymphoma
Buecklein, V
Blumenberg, V
Winkelmann, M.
Ackermann, J.
Froelich, L.
Schmidt, C.
Hildebrand, F.
Rejeski, K.
Ruzicka, M.
Mueller, N.
von Baumgarten, L.
Schoeberl, F.
Hildebrandt, M.
Humpe, A.
Hoster, E.
von Bergwelt, M.
Kunz, W. G.
Subklewe, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 258 - 258
[44] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
Liang, Aibin
Zhou, Lili
Li, Ping
Yu, Wenjuan
Yang, Min
Xu, Yangyang
Ye, Shiguang
Zhu, Judy
Huang, Jiaqi
Zhang, Yan
Li, Lanfang
Zhao, Jing
Li, Jing
Zheng, Chengxiao
Zhu, Kevin
Lan, Liping
Zhang, Huilai
Zhou, Daobin
Yao, Yihong
Jin, Jie
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
Wang, Song-yun
An, Wan-hua
Wang, Ze-song
Wang, Wan-li
Zhang, Bin
Xu, Kai-lin
Guo, Shu-li
Gao, Ming
Li, Bo
Huang, Lei
Tian, Huan-huan
Guo, Wen-yi
Wang, Hui-rui
FRONTIERS IN IMMUNOLOGY, 2024, 15
[46] Molecular disease monitoring in patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell therapy.
Colton, Meryl D.
Purev, Enkhtsetseg
Haverkos, Bradley
Bair, Steven Michael
Jasem, Jagar
Schliekelman, Mark Jason
Kamdar, Manali K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[47] Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Zhang, Xian
Yang, Junfang
Li, Wenqian
Zhang, Gailing
Su, Yunchao
Shi, Yanze
Song, Dan
Zhang, Min
He, Jiujiang
Xu, Li
Li, Jingjing
Lu, Xinan
Li, Jianqiang
Li, Xiangqun
Xu, Zhongwei
Li, Ziyu
Lu, Peihua
BLOOD, 2020, 136
[48] CAR T-cell therapy for B-cell lymphoma
Denlinger, Nathan
Bond, David
Jaglowski, Samantha
CURRENT PROBLEMS IN CANCER, 2022, 46 (01)
[49] Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report
Cai, Ziyi
Zou, Dongmei
Ma, Qiang
Sun, Wanling
Guo, Yixian
SAGE OPEN MEDICAL CASE REPORTS, 2025, 13
[50] Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature
Zhao, Aiqi
Zhao, Mingzhe
Qian, Wenbin
Liang, Aibin
Li, Ping
Liu, Hui
FRONTIERS IN IMMUNOLOGY, 2023, 13

← 1 2 3 4 5 →